Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

6/24/24 7:16:12 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $TRIB alert in real time by email

Get the next $TRIB alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$TRIB

Date	Price Target	Rating	Analyst

More analyst ratings

$TRIB
Press Releases

Fastest customizable press release news feed in the world

View All

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares ("MVPHS") of $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on the Nas

2/20/26 5:00:00 PM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company's American Depositary Shares ("ADSs") for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on

2/13/26 5:00:00 PM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

Approval Marks Final Regulatory Milestone Required to Enable Launch of Upstream Manufacturing Activities Under New Offshored & Outsourced Production Model Expected to Drive Gross Margin Expansion, Improve Working Capital Efficiency, and Enhance Long‑Term Scalability Represents a Key Final Component of the Company's Comprehensive Transformation Plan DUBLIN, Ireland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has now received full regulatory approval for the commencement of upstream manufacturing activities for

2/10/26 1:28:10 PM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

$TRIB
Financials

Live finance-specific insights

View All

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

2/20/26 5:00:00 PM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

2/13/26 5:00:00 PM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

2/10/26 1:28:10 PM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

$TRIB
Leadership Updates

Live Leadership Updates

View All

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director. Mr. Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance across the infrastructure, energy, shipping, and cleantech sectors. He currently serves as Chief Financial Officer of Deriva Energy LLC, one of the largest independent renewable power producers in the United States and a Brookfield portfolio company. His previous

8/21/25 9:00:23 AM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan. With substantial progress in developing its differentiated and

3/13/25 7:30:00 AM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief Commercial Officer. Mr. Donohue brings more than 25 years of experience in the sales and marketing of healthcare products. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We are resolute in continuing to execute on our transformation agenda, which will drive greater performance and profitability in our existing product lines, including supporting continued growth in our newest r

9/3/24 9:55:00 AM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$TRIB

Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$TRIB

$TRIB
SEC Filings

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 424B3 filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

$TRIB
Press Releases

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

$TRIB
Financials

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

$TRIB
Leadership Updates

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

$TRIB
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

SEC Form SC 13D filed by Trinity Biotech plc

Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $TRIB

Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $TRIB

$TRIB SEC Filings

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 424B3 filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

$TRIB Press Releases

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

$TRIB Financials

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

$TRIB Leadership Updates

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

$TRIB Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

SEC Form SC 13D filed by Trinity Biotech plc

Recent Analyst Ratings for
$TRIB

Recent Analyst Ratings for
$TRIB

$TRIB
SEC Filings

$TRIB
Press Releases

$TRIB
Financials

$TRIB
Leadership Updates

$TRIB
Large Ownership Changes